Minor Trauma Led to Death in Pradaxa Patient

Dabigatran etexilate is an oral anticoagulant that acts as a direct, competitive thrombin inhibitor. It does not require routine monitoring and has been approved by the FDA for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Note, however, that no effective reversal agent for dabigatran in the event of catastrophic hemorrhage has been identified.

via Medical News:Minor Trauma Led to Death in Pradaxa Patient – in Neurology, Head Trauma from MedPage Today.

On the article’s webpage you’ll find a link to download a PDF copy of the source article.

Mortality Risk Quantified for Diabetes Plus Kidney Disease

This meta-analysis found that the presence of chronic kidney disease strongly predicted mortality risk in patients with type 2 diabetes. Chronic kidney disease more than doubles mortality risk in patients with type 2 diabetes, researchers found. In an analysis of nearly two dozen randomized controlled trials involving diabetic patients, the highest mortality rates were observed in those trials that required the inclusion of patients with renal disease, according to Marc Pfeffer, MD, PhD, of Brigham and Women’s Hospital in Boston, and colleagues. Trials that selected for patients with elevated serum creatinine or impaired estimated glomerular filtration rate eGFR had mortality rates of 5.9 to 8.2 per 100 patient-years, whereas the rest of the trials had rates no higher than 3.3, the researchers reported online in the Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease.

via Medical News:Mortality Risk Quantified for Diabetes Plus Kidney Disease – in Cardiovascular, Diabetes from MedPage Today.

FDA Adds Diabetes Warning to Statin Labels

The diabetes warning has been rumored as a possibility since the findings from the JUPITER trial of rosuvastatin revealed an unexpected 27% increase in new onset diabetes among patients randomized to the statin.That finding was especially perplexing because JUPITER was a study of statins in patients who had no history of cardiovascular disease, the so-called healthy patient trial. Moreover, based on the JUPITER results, the FDA approved rosuvastatin for primary prevention.The FDA said hyperglycemia was also observed among patients treated with 40-mg atorvastatin in a substudy of PROVE-IT TIMI 22, and a meta-analysis of data from 13 statin trials “reported that statin therapy was associated with a 9% increased risk for incident diabetes.”

via Medical News:FDA Adds Diabetes Warning to Statin Label – in Cardiovascular, Dyslipidemia from MedPage Today.

Effect of Aspirin on Vascular and Nonvascular Outcomes Meta-analysis

Conclusion: Despite important reductions in nonfatal MI, aspirin prophylaxis in people without prior CVD does not lead to reductions in either cardiovascular death or cancer mortality. Because the benefits are further offset by clinically important bleeding events, routine use of aspirin for primary prevention is not warranted and treatment decisions need to be considered on a case-by-case basis.

via Arch Intern Med — Abstract: Effect of Aspirin on Vascular and Nonvascular Outcomes: Meta-analysis of Randomized Controlled Trials, February 13, 2012, Seshasai et al. 172 3: 209.

Latin America: Where the world’s jobs are

Latin America: Where the world’s jobs are – CSMonitor.com.

So far, 200 entrepreneurs from 30 different countries have traveled to Chile to try to get their ideas off the ground through Start-Up Chile. The program aims to fund 1,000 entrepreneurs by 2014, and not only benefits the grantees – 80 percent of whom are foreigners – but is a boon to Chile, too, says spokeswoman Brenna Loury.

Interesting little article that offers minimal facts to back up the author’s assertion in the title.  How does 200 entrepreneurs equal “where the world’s jobs are”?